Tel Aviv, Israel / Vancouver, Canada, April 04, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the pricing of its United States only public offering made on a reasonable best efforts…


Previous articleAlgernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
Next articlePT403 – Understanding the Brain: Psychedelic Neuroscience Demystified